ABUS - Arbutus Biopharma Corp

QQQ $ 633.55 $ 4.83 (0.77 %)

DIA $ 476.83 $ 1.80 (0.38 %)

SPY $ 687.33 $ 1.82 (0.27 %)

TLT $ 92.10 $ 0.24 (0.26 %)

GLD $ 364.95 $ -2.63 (-0.72 %)

Previous Close

$ 4.58

Open

$ 4.47

Bid

$ 4.29 x 1,000

Ask

$ 4.69 x 1

Day's Range

$ 4.40 - $ 4.61

52 Week Range

$ 2.71 - $ 5.10

Volume

689,169

Average Volume

Market Cap

877.98M

Beta (5Y Monthly)

$ 0.55

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2025	06-30-2025	10-Q
2	05-14-2025	03-31-2025	10-Q
3	03-27-2025	12-31-2024	10-K
4	11-06-2024	09-30-2024	10-Q
5	08-08-2024	06-30-2024	10-Q
6	05-02-2024	03-31-2024	10-Q
7	03-05-2024	12-31-2023	10-K
8	11-07-2023	09-30-2023	10-Q
9	08-03-2023	06-30-2023	10-Q
10	05-04-2023	03-31-2023	10-Q
11	03-02-2023	12-31-2022	10-K
12	11-09-2022	09-30-2022	10-Q
13	08-04-2022	06-30-2022	10-Q
14	05-05-2022	03-31-2022	10-Q
15	03-03-2022	12-31-2021	10-K
16	11-04-2021	09-30-2021	10-Q
17	08-05-2021	06-30-2021	10-Q
18	05-05-2021	03-31-2021	10-Q
19	03-04-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-07-2020	06-30-2020	10-Q
22	05-11-2020	03-31-2020	10-Q
23	03-05-2020	12-31-2019	10-K
24	11-06-2019	09-30-2019	10-Q
25	08-05-2019	06-30-2019	10-Q
26	05-06-2019	03-31-2019	10-Q
27	03-07-2019	12-31-2018	10-K
28	11-07-2018	09-30-2018	10-Q
29	08-03-2018	06-30-2018	10-Q
30	05-04-2018	03-31-2018	10-Q
31	03-16-2018	12-31-2017	10-K
32	11-02-2017	09-30-2017	10-Q
33	08-03-2017	06-30-2017	10-Q
34	05-04-2017	03-31-2017	10-Q
35	03-22-2017	12-31-2016	10-K
36	11-03-2016	09-30-2016	10-Q
37	08-04-2016	06-30-2016	10-Q
38	05-04-2016	03-31-2016	10-Q
39	03-09-2016	12-31-2015	10-K
40	11-05-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Chardan Capital Maintains Buy on Arbutus B...
08/11/2025 11:22:09

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Arbutus Biopharma Q2 EPS $0.01 Beats $(0.0...
08/06/2025 11:40:28

Arbutus Reacquires Greater China Rights To...
06/25/2025 11:33:14

Arbutus Biopharma Q1 EPS $(0.13) Misses $(...
05/14/2025 11:36:28

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $...

Arbutus's Imdusiran Plus VTP-300 And Low-D...
05/07/2025 07:10:36

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV...

Arbutus Biopharma To Present Key Hepatitis...
04/23/2025 06:29:12

Chardan Capital Maintains Buy on Arbutus B...
03/28/2025 12:39:04

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Arbutus Biopharma FY 2024 GAAP EPS $(0.38)...
03/27/2025 11:43:17

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.38) per share. This is a 13.64 percent increase over losses of...

Roviant Sciences Subsidiary, Genevant Scie...
03/03/2025 14:16:36

Arbutus Biopharma Appoints Lindsay Androsk...
02/25/2025 12:47:59

In addition to Ms. Androski, four new directors have joined the board: Robert Alan Beardsley, Joseph Bishop, Matthew Gline and ...

HC Wainwright & Co. Reiterates Buy on Arbu...
01/21/2025 13:07:39

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Arbutus Biopharma Held $123M In Cash Balan...
01/13/2025 12:46:44

Imdusiran (RNAi therapeutic)At the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® in Novembe...

Whitefort Capital Sends Letter To Arbutus ...
12/03/2024 13:24:00

Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explo...

walmart-to-rally-more-than-15-here-are-10-top-analyst-forecasts-for-wednesday

Walmart To Rally More Than 15%? Here Are 1...
11/20/2024 12:45:06

Chardan Capital Maintains Buy on Arbutus B...
11/20/2024 10:58:45

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $4....

HC Wainwright & Co. Reiterates Buy on Arbu...
11/18/2024 12:17:37

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Arbutus And Barinthus Bio Report IM-PROVE ...
11/15/2024 16:02:56

HC Wainwright & Co. Reiterates Buy on Arbu...
11/07/2024 13:05:54

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Chardan Capital Maintains Buy on Arbutus B...
11/07/2024 00:21:10

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $4 ...

As Of September 30, 2024, Arbutus Had Cash...
11/06/2024 12:43:07